Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Novartis Pharmaceuticals
The study was designed as a multi-center, open-label, randomized, active-controlled, Phase III trial. Participants were randomized to either JDQ443 or docetaxel. Participants randomized to the docetaxel arm had the opportunity to cross over to JDQ443 at disease progression per RECIST 1.1 by local investigator assessment. The study population included adult participants with locally advanced or metastatic (stage IIIB/IIIC or IV) KRAS G12C mutant non-small cell lung cancer (by tissue or plasma as determined by a Novartis-designated central laboratory or accepted local tests) who had received prior platinum-based chemotherapy and prior immune checkpoint inhibitor therapy administered either in sequence or as combination therapy. Approximately 360 participants were planned to be randomized to JDQ443 or docetaxel in a 1:1 ratio stratified by prior line of therapy and ECOG performance status. Following the decision to halt enrollment for business reasons, a total of 95 participants were randomized.
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
